Organic Active Ingredients TRIZ Cases

Substituted pyrrolopyridines inhibit TLR9 while preserving TLR7 and TLR8 selectivity, with stability and bioavailability suited to fibrotic disease therapy.

PD-L1-guided paclitaxel nanoparticles combine antibody targeting and chemotherapy to address resistance and improve survival in cancer treatment.

Selective olutasidenib dosing for R132X-mutant AML or MDS sustains 2-HG inhibition and clinical response without dose-limiting toxicities.

Defined LPEI-PEG conjugation reduces polyplex heterogeneity and serum interaction while enabling selective nucleic acid delivery to target cells.

Combining L-asparaginase with a ferroptosis inducer targets ENKTCL metabolic vulnerabilities to improve efficacy in advanced-stage disease.

Targeted retinal dsRNA degrades TTR mRNA in the RPE, cutting expression 40-60% while avoiding IL-6 and TNF-alpha inflammatory signals.

PLGA microspheres tune polymer composition to deliver progestogen with linear release over days, avoiding burst and lag phases.

C-circle assay identifies ALT-positive tumors for PRIMA-1 or APR-246 treatment that restores p53 activity and helps overcome drug resistance.

Phosphorylated D-chiro-inositol derivatives modulate developmental signaling, inhibit kinases, and regulate PKM2 to reduce fetal defects and cancer growth.

Reducing or chelating agents limit lipid-mRNA adducts during formulation, improving mRNA stability and translation competency.

Salt, ester, and conjugate forms of psilocin improve stability, crystallinity, and solubility while enabling calmer therapeutic dosing.

Micronized magnesium stearate enables stable ASA inhalation powder with preserved dispersibility and pulmonary delivery under varied storage conditions.

A KRas-binding fusion protein combines tumor-cell penetration with lysosome targeting to degrade wild-type and mutant KRas in tumors.

Targeted SNV testing in EPHB4, PIK3R4, PIK3R6, mTOR, and ARAF improves lymphatic anomaly diagnosis and guides inhibitor selection.

Amide-based solvents stabilize Trolox salt formation with chiral resolving agents, enabling scalable separation at 98% ee or higher.

Single-mutation-specific siRNAs silence mutant p53 without hitting wild-type p53, reducing side effects and slowing tumor growth.

A phosphatidylcholine liposomal joint injection maintains a liquid phase near body temperature to extend pain relief and reduce repeat dosing.

rAAV delivery of ASPA raises spinal cord aspartate to support oxidative phosphorylation, improve motor function, and extend survival in ALS.

Residue-specific NLRP3-binding compounds suppress inflammation while improving therapeutic specificity for cancer, inflammaging, and metabolic disorders.

Controlled oxygen and ammonium sulfate keep ready-to-use carboplatin infusion solutions stable at room temperature with low impurities.

A permeation-enhanced transdermal CBD gel treats DEE seizures and behavioral symptoms while avoiding GI issues and first-pass metabolism.

Permeation enhancers such as cyclodextrins, fatty acids, and nonionic surfactants help active ingredients cross the stratum corneum more effectively.

An apixaban ODT balances rapid disintegration and tablet hardness to improve swallowing while maintaining consistent dissolution and absorption.

Deuterium-labelled Trapidil derivatives extend half-life and lower plasma peaks to reduce side effects in Parkinson's treatment.

Novel heteroaryl amide compounds inhibit CD38 to preserve cellular NAD+ and reduce TRPM2 activation with fewer side effects.

Specific HCl, HBr, potassium, and sodium salts of Compound 1 improve IDO inhibitor solubility and stability for pharmaceutical use.

Novel Formula I Kv7.2/7.3/7.5 openers raise seizure threshold and aim to improve epilepsy treatment efficacy with fewer side effects.

Smartphone sensor data and machine learning enable frequent at-home SMA motor assessment without costly clinic visits.

Novel 3-aminoisoxazolopyridine compounds inhibit IDO1 and TDO to restore tumor immunity and improve combination cancer therapy.

Selective alpha-3 GABAA antagonist steroids block chloride flux to curb excessive food intake and weight gain linked to obesity disorders.

Selective oral Compound I compositions inhibit MK2 to reduce cytokine production and inflammatory markers in immune conditions.

Capillary electrophoresis and nanofiltration refine HPBCD substitution patterns to improve selective guest molecule solubilization and delivery.

Amorphous solid dispersions with stabilizing polymers speed oral dissolution while limiting crystallization during manufacturing and storage.

An acidified intranasal nalbuphine composition raises solubility for therapeutic dosing in small volumes, improving pain treatment compliance.

Hydrolyzable opioid conjugates enable controlled release over weeks to months, reducing dosing frequency, abuse risk, and compliance problems.

A bioadhesive soft gel releases estradiol in the lower vagina to relieve VVA symptoms while limiting uterine transport and systemic absorption.

Engineered anti-TNFα antibodies dissociate at acidic pH to limit immune complexes, reduce immunogenicity, and maintain serum levels.

Small antiviral compounds replace complex natural polymers to retain antiviral activity while simplifying production and lowering cost.

By blocking HPK1 to boost T cell proliferation and cytokine signaling, this case addresses antiviral limits caused by viral variability.

Targets the IGPD enzyme in M. tuberculosis to curb bacterial growth while minimizing human cross-reactivity and resistance risk.

A prodrug-loaded adhesive matrix patch enables stable transdermal delivery of acetaminophen and ibuprofen despite poor native skin permeability.

Non-complementary pre-miRNA units spaced apart improve immune checkpoint knockdown while limiting off-target silencing and vector recombination.

Solid-state mechanochemical synthesis creates sub-200 nm drug nanoparticles in a carrier matrix to improve dissolution, purity, and safety.

Specific aldehydes boost menthol-like cooling while reducing bitter and astringent taste in food, oral care, and body care compositions.

Ritonavir boosts lonafarnib exposure so HDV viral load can be reduced at lower doses while limiting gastrointestinal side effects.

Introducing oxygen into the tetrahydroindazole ring improves microsomal stability and lowers CYP inhibition for cancer and antiviral compounds.

A fixed-dose brimonidine and timolol eye drop lowers intraocular pressure while simplifying glaucoma treatment and reducing ocular side effects.

DHMBA protects renal proximal tubular mitochondria by lowering intramitochondrial ROS, limiting fragmentation, and restoring ATP production.

A five-herb composition combines Ashwagandha, Turmeric, Lemon Balm, Rhodiola, and Bilberry to improve recovery and support cognitive function.

Selective GABAA γ1 PAMs restore GABAergic signaling for neurological disorders while reducing side effects linked to non-selective benzodiazepines.